Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers, 18-60 years of age; no clinically significant findings reported following detailed physical examination, medical history, vital signs, clinical laboratory tests, and ECGs as deemed by the PI~* Body mass index (BMI) in the range of 18 to 32 kg/m2 (inclusive) and weighing at least 50 kg~* Non-smokers / non-users of nicotine containing products for at least the previous 3 months~* Agreement to use birth control during the study and 3 months post last visit~* Able to comply with all protocol requirements and procedures~Exclusion Criteria:~* Clinically significant abnormalities found during physical examination, medical history review, ECGs (including QTcf interval \> 450 msec), vital signs and laboratory tests (including positive test for HIV, hepatitis B and/or C)~* History of any serious allergic reaction to any medication~* Participated in a previous clinical trial with an investigational product in the last 60 days~* Any blood or plasma donation or other loss of blood at a volume exceeding 500 mL within 3 months before dosing~* History of drug or alcohol abuse in the last 2 years and positive test for drug abuse~* Use of any systemic medication within the past 2 weeks, including use of herbal products~* Pregnant or lactating women~* Any other issue which, in the opinion of the PI, will make the subject ineligible for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
- Cohort 2 (Type: EXPERIMENTAL): Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
- Cohort 3 (Type: EXPERIMENTAL): Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
- Cohort 4 (Type: EXPERIMENTAL): Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
- Cohort 5 (Type: EXPERIMENTAL): Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
- Cohort 6 (Type: EXPERIMENTAL): Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
- Cohort 7 - Bone Marrow Cohort (Type: EXPERIMENTAL): All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).